Résumé
@#BACKGROUND: True alarm rate of the Code Blue cases is at a low level in the Dr. Beh?et Uz Children''s Hospital in ?zmir. This study aims to analyse the use of the Code Blue alarm cases in the children''s hospital.METHODS: This retrospective clinical study evaluated the age and the gender of the cases, the arriving time of the Code Blue team, the date and time of the Code Blue Call, the reasons of the Code Blue Call, and the verifi cation which were all obtained from the Code Blue forms of the hospital dated between January 2014 and January 2015. The data of 139 Code Blue cases'' forms were investigated and was divided into two groups: before and after the education containing 88 and 51 cases, respectively.RESULTS: Conversive disorder (26％ to 13％,P<0.01), syncope (21.5％ to 19.6％,P<0.01), convulsion (17％ to 13.7％,P<0.01), hypoglycemia (4.5％ to 3.9％,P<0.01), anxiety (4.5％ to 1.9％, P<0.01), head trauma due to syncope (4.5％ to 0％), cardiac arrest (1.1％ to 0％), respiratory difficulties (2.2％ to 1.9％,P<0.01), suspicion of myocardial infarction (2.2％ to 1.9％,P<0.01), fall from stairs (2.2％ to 0％) and agitation cases (1.1％ to 0％) were reduced, however, the hypertension cases were dramatically increased (3.4％ to 29.4％,P<0.01) owing to the hospital staff''s education. The Pearson''s correlation coeffi cient before and after education was 0.837. About 97.8％ of the Code Blue cases were false calls with female greater than male (P<0.01).CONCLUSION: The results of this study show that more education is required for the hospital''s staff and a new color code that is to say pre-diagnosis team should be formed.
Résumé
Purpose We aimed to compare the effect and feasibility of a combined therapy with tamsulosin hydrochloride plus meloxicam, and tamsulosin hydrochloride alone in patients with benign prostate hyperplasia symptoms and impact on nocturia and sleep quality. Materials and Methods Four hundred male patients were included in this study between 2008 and 2011. Patients were randomly divided into two groups: one received tamsulosin hydrochloride 0.4 mg (Group 1, 200 patients) and the other tamsulosin hydrochloride 0.4 mg plus meloxicam 15 mg (Group 2, 200 patients) prospectively. Patients were evaluated for benign prostate hyperplasia (BPH) symptoms according to the American Urological Association clinical guidelines and sleep quality according to Pittsburgh Sleep Quality Index (PSQI). Patients were reevaluated after three months of treatment. The International Prostatic Symptom Score (IPSS), IPSS-Quality of Life (IPSS-QoL), maximal urinary flow rates (Qmax), average urinary flow rates (AFR), post void residual urine volumes (PVR), nocturia and Pittsburgh Sleep Quality Score (PSQS) were recorded at baseline and after three months. Results Mean age was 63.3 ± 6.6 and 61.4 ± 7.5 years in groups 1 and 2, respectively (p = 0.245). There were no statistically significant differences between both groups. Also, baseline prostate specific antigen (PSA), prostate volume, creatinine, International Prostatic Symptom Score (IPSS), IPSS-Quality of Life (IPSS-QoL), maximal urinary flow rates (Qmax), average urinary flow rates (AFR), post void residual urine volumes (PVR), nocturia and Pittsburgh Sleep Quality Score (PSQS) were similar in both groups. In addition, the total IPSS, IPSS-QoL, PVR, nocturia, and PSQS were significantly lower in Group 2 compared with Group 1 after treatment (p < 0.05). Qmax and AFR were higher significantly in Group 2 compared with Group 1 after treatment (p < 0.05). Conclusions Cyclooxygenase (COX)-2 inhibitors ...